Browse Studies — Arctuva

Phase 1

A Phase Ib Trial With Dose Expansion of Epcoritamab in Combination With Ibrutinib in Refractory/Recurrent CNS Lymphoma (EIFEL-Trial)

The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects…

Primary Central Nervous System Lymphoma (PCNSL)Primary Central Nervous System LymphomaRelapsed Primary Central Nervous System Lymphoma+4 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07082868

Phase 1

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advance…

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Diffuse Large B Cell Lymphoma (DLBCL)+6 more

Estimated

~$10 – $8,750

Nurix Therapeutics, Inc.NCT05131022

Phase 1

A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients wit…

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)+5 more

Estimated

~$10 – $8,750

Nurix Therapeutics, Inc.NCT04830137